Carl Zeiss Meditec (AFX) Stock Price, News & Analysis

Company Overview

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

Key Stats

• Today's Range: €30.08 to €31.28
• 50-Day Range: €27.34 to €32.88
• 52-Week Range: €54.60 to €123.75
• Volume: 184,307 shs
• Average Volume: 94,405 shs
• Market Capitalization: €2.82 billion
• P/E Ratio: 16.19
• Dividend Yield: 1.82%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: ETR:AFX
• CIK: N/A
• Web: www.zeiss.com
• Phone: +49-3641-2200
• Fax: N/A
• Employees: 4,950
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): €1.87
• Trailing P/E Ratio: 16.19
• Forward P/E Ratio: 10.37
• P/E Growth: 2.83
• Net Income: €185.59 million
• Net Margins: 4.40%
• Pretax Margin: N/A
• Return on Equity: 5.52%
• Return on Assets: 7.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: 2.47

Sales & Book Value

• Annual Sales: €2.69 billion
• Price / Sales: 1.05
• Cash Flow: €0.02 per share
• Price / Cash Flow: 1,398.28
• Book Value: €24.43 per share
• Price / Book: 1.24

Miscellaneous

• Outstanding Shares: 93,178,085
• Free Float: N/A
• Market Cap: €2.82 billion
• Optionable: Not Optionable
• Beta: 1.36